Ticker brief
SXTP
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
7
authors 14d
2
crowd 14d
·
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-04 → 2026-10-06 · now -0.43 (−1 bearish … +1 bullish)
Who spoke2
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 6 | -0.36 |
| @OpenOutcrier | C | · | 1 | -0.45 |
Recent signals7of 7 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-06 | @BiopharmIQ | -0.35 | SXTP caps enrollment below plan and delays babesiosis results to January 2027, though no safety issue emerged. | · | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | -0.50 | Biotech mover list quantifies the largest negative opening reactions and their associated catalysts. | · | tweet ↗ |
| 2026-10-06 | @OpenOutcrier | -0.45 | Reports SXTP falling 26.4% premarket ahead of interim trial results. | · | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | -0.45 | Explains caution on SXTP using small sample size, endpoint variability and limited cash. | · | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | -0.40 | Names SXTP as one of the model's least-favored potential movers among upcoming readouts. | · | tweet ↗ |
| 2026-10-05 | @BiopharmIQ | -0.45 | Explains caution on SXTP using small sample size, endpoint variability and limited cash. | · | tweet ↗ |
| 2026-10-04 | @BiopharmIQ | +0.00 | Lists biotech names with Phase 2 or Phase 3 readouts expected in Q4 2026. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.